<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1191">
  <stage>Registered</stage>
  <submitdate>28/03/2006</submitdate>
  <approvaldate>31/03/2006</approvaldate>
  <actrnumber>ACTRN12606000116527</actrnumber>
  <trial_identification>
    <studytitle>Randomised double-blind controlled trial of the use of daily sildenafil (Viagra) in men with early prostate cancer treated with radiation, for the prevention of subsequent erectile dysfunction.</studytitle>
    <scientifictitle>Randomised double-blind controlled trial of the use of daily sildenafil (Viagra) in men with early prostate cancer treated with radiation, for the prevention of subsequent erectile dysfunction.</scientifictitle>
    <utrn />
    <trialacronym>VEPCaPSED</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to receive either sildenafil (Viagra) after their radiation treatment is complete and will commence 1 month after completion of all treatment for prostate cancer.  Patients will be commenced on 50mg sildenafil taken orally once daily.  If there are no adverse events after 1 month the dose will be increased to 100mg (two 50mg tablets) taken orally daily for a total period of medication of 24 weeks.  The trial medication will then cease.</interventions>
    <comparator>Patients will be randomised to receive placebo after their radiation treatment is complete and will commence 1 month after completion of all treatment for prostate cancer.  Patients will be commenced on placebo (1 tablet) taken orally once daily. </comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Erectile function assessed using the International Index of Erectile Function (IIEF)</outcome>
      <timepoint>At the start of the study, at commencement of viagra/placebo and at 1, 3, 6, 12 and 24 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Testosterone and Follicle Stimulating Hormone (FSH).</outcome>
      <timepoint>Measured at commencement of Viagra/placebo and at 6, 12 and 24 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adenocarcinoma of the prostate, planned radiation tretment with curative intent, can speak and read English well enough to complete self-reporting questionnaires, score of greater than 10 in the erectile domain score of the IIEF. </inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Men with absent erectile function, high risk disease: &gt;T3a or PSA &gt;20 or Gleason combined score &gt;7, men with contraindications for Viagra, long term androgen deprivation planned after completion of radiotherapy, past history of radical prostatectomy, anatomic deformity of the penis: Peyronie's disease, cavernosal fibrosis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Trial pharmacist will randomise patients and prepare active agent or placebo.  Only authorised clinical trial pharmacy staff will be aware of the treatment allocation.  Dispensing labels of medication will be marked 'active/placebo'.  The active agent and placebo will be identical in appearance.</concealment>
    <sequence>Computer generated randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>12/03/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>William Buckland Radiotherapy Centre</primarysponsorname>
    <primarysponsoraddress>Alfred Hospital, Commercial Road, Melbourne, 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Australia</fundingname>
      <fundingaddress>38-42 Wharf Road, West Ryde, NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>William Buckland Radiotherapy Centre</fundingname>
      <fundingaddress>Alfred Hospital, Commercial Road, Melbourne, 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>N/A</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>All staff and patients will be blinded from allocation of active agent/placebo.  Only authorised clinical trial pharmacy staff will have access to this information.  If a medical emergency requires unblinding, the principal investigator is required to provide authorisation for clinical trial pharmacy staff to unblind.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>5/03/2002</ethicapprovaldate>
      <hrec>176/01</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/09/2004</ethicapprovaldate>
      <hrec> 04/34</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jeremy Millar</name>
      <address>William Buckland Radiotherapy Centre
Alfred Hospital
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 90762337</phone>
      <fax />
      <email>Jeremy.Millar@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Robin Smith</name>
      <address>William Buckland Radiotherapy Centre
Alfred Hospital
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 90762360</phone>
      <fax />
      <email>robin.smith@wbrc.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>